GC LabTech Launches Partnership with 1health.io to Deploy Innovative Lab Tests Direct-to-Consumer
GC LabTech, a subsidiary of GC Biopharma of South Korea, and a CAP & ISO accredited, FDA-registered specialty laboratory with life-saving plasma tests, selects 1health.io, an industry-leading software company revolutionizing the way laboratories expand testing into the at-home markets, to deliver its innovative new lab tests direct-to-consumers.
- GC LabTech, a subsidiary of GC Biopharma of South Korea, and a CAP & ISO accredited, FDA-registered specialty laboratory with life-saving plasma tests, selects 1health.io, an industry-leading software company revolutionizing the way laboratories expand testing into the at-home markets, to deliver its innovative new lab tests direct-to-consumers.
- The new partnership between 1health and GC LabTech enables GC LabTech to sell its innovative new health and wellness tests into the $1 billion direct-to-consumer lab testing market, which is forecasted to grow to $8.8 billion by 2031 according to research group Transparency Marketing in its report North America Direct-to-Consumer Laboratory Testing Market Insights, 2021-2031 published in Q1 2022.
- Known for its highly accurate, optimized efficiency, and fast turnaround service, GC LabTech is applying its high-performance lab testing capabilities to the direct-to-consumer segment.
- Previously, GC Lab Tech had explored the direct-to-consumer market but found it did not have the front-end or back-end infrastructure to launch the tests to the consumer.